Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Interferons. New additions and indications for use

R Stadler¹, Z Ruszczak

¹Department of Dermatology, Minden's Medical Center, Germany.

Dermatologic Clinics

|January 1, 1993

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Evaluation of Sézary cell marker expression and cell death behaviour upon in vitro treatment by flow cytometry in Sézary syndrome patients.

Experimental dermatology·2024

Same author

Health-related quality of life and its influencing factors in patients with primary cutaneous B-cell lymphomas: A multicentric study in 100 patients.

Journal of the European Academy of Dermatology and Venereology : JEADV·2024

Same author

Adenoma Detection Rate on Colonoscopy: an Argument for Focused Screening?

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract·2022

Same author

Learning from itch - epidermolysis bullosa is a genetically determined barrier disruption and a chronic inflammatory disease.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021

Same author

[Calprotectin-a key for diagnosing chronic inflammatory bowel disease in inflammatory dermatoses? : Three case reports].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2021

Same author

Corrigendum: Management of primary cutaneous lymphoma patients during COVID-19 pandemic: EORTC CLTF guidelines.

Journal of the European Academy of Dermatology and Venereology : JEADV·2020

Natural and recombinant interferons (IFN-alpha, IFN-beta, IFN-gamma) show clinical efficiency for skin disorders. This review proposes novel therapeutic schedules for skin tumors and inflammatory conditions.

Area of Science:

Immunology
Dermatology
Biotechnology

Background:

Cytokines, including interferons, are increasingly available for clinical applications.
Interferons (IFNs) have the most extensive clinical experience among cytokines.
Natural and recombinant IFNs encompass alpha, beta, and gamma subtypes.

Purpose of the Study:

To discuss the clinical efficacy and therapeutic value of IFNs in dermatology.
To evaluate IFNs administered alone or in combination therapy for skin disorders.
To propose novel therapeutic schedules for specific skin conditions.

Main Methods:

Review of clinical data on interferon therapy for skin disorders.
Analysis of efficacy for natural and recombinant interferon-alpha, -beta, and -gamma.

Related Experiment Videos

Evaluation of combination therapy approaches.

Main Results:

Interferons demonstrate clinical efficiency in treating various skin disorders.
Specific therapeutic schedules are effective for cutaneous T-cell lymphoma and malignant melanoma.
Interferons show promise for managing inflammatory skin conditions.

Conclusions:

Interferons are valuable therapeutic agents in dermatology.
Novel treatment schedules can optimize interferon therapy for skin tumors and inflammatory diseases.
Further research into combination therapies may enhance outcomes.